{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:41:59Z","timestamp":1793108519207,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41577-026-01361-8","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T11:22:00Z","timestamp":1790594520000},"page":"784-786","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drugging the immune system: principles of immunopharmacology"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0477-1956","authenticated-orcid":false,"given":"E. John","family":"Wherry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"1361_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.trecan.2024.10.009","volume":"11","author":"K Adam","year":"2025","unstructured":"Adam, K., Butler, S. C., Workman, C. J. & Vignali, D. A. A. Advances in LAG3 cancer immunotherapeutics. Trends Cancer 11, 37\u201348 (2025).","journal-title":"Trends Cancer"},{"key":"1361_CR2","doi-asserted-by":"publisher","first-page":"ltaf015","DOI":"10.1093\/immadv\/ltaf015","volume":"5","author":"L Sheriff","year":"2025","unstructured":"Sheriff, L. et al. Lag3 and PD-1 pathways preferentially regulate NFAT-dependent TCR signalling programmes during early CD4+ T cell activation. Immunother. Adv. 5, ltaf015 (2025).","journal-title":"Immunother. Adv."},{"key":"1361_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nri701","volume":"2","author":"LSK Walker","year":"2002","unstructured":"Walker, L. S. K. & Abbas, A. K. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2, 11\u201319 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"1361_CR4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.cell.2010.02.029","volume":"140","author":"C Nathan","year":"2010","unstructured":"Nathan, C. & Ding, A. Nonresolving inflammation. Cell 140, 871\u2013882 (2010).","journal-title":"Cell"},{"key":"1361_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"1361_CR6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.ccell.2023.03.009","volume":"41","author":"JA Pai","year":"2023","unstructured":"Pai, J. A. et al. Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. Cancer Cell 41, 776\u2013790.e7 (2023).","journal-title":"Cancer Cell"},{"key":"1361_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"1361_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1098","volume":"352","author":"MG Netea","year":"2016","unstructured":"Netea, M. G. et al. Trained immunity: A program of innate immune memory in health and disease. Science 352, aaf1098 (2016).","journal-title":"Science"},{"key":"1361_CR9","doi-asserted-by":"publisher","first-page":"281ra43","DOI":"10.1126\/scitranslmed.aaa2293","volume":"7","author":"D Furman","year":"2015","unstructured":"Furman, D. et al. Cytomegalovirus infection enhances the immune response to influenza. Sci. Transl. Med. 7, 281ra43 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1361_CR10","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41577-023-00874-w","volume":"23","author":"K Donald","year":"2023","unstructured":"Donald, K. & Finlay, B. B. Early-life interactions between the microbiota and immune system: impact on immune system development and atopic disease. Nat. Rev. Immunol. 23, 735\u2013748 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1361_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2014.12.020","volume":"160","author":"P Brodin","year":"2015","unstructured":"Brodin, P. et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 160, 37\u201347 (2015).","journal-title":"Cell"},{"key":"1361_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/ni.3371","volume":"17","author":"EJ Carr","year":"2016","unstructured":"Carr, E. J. et al. The cellular composition of the human immune system is shaped by age and cohabitation. Nat. Immunol. 17, 461\u2013468 (2016).","journal-title":"Nat. Immunol."},{"key":"1361_CR13","doi-asserted-by":"publisher","unstructured":"Lee, M. E. et al. Deep learning representations of human immune health for precision immunology. Preprint at bioRxiv https:\/\/doi.org\/10.64898\/2026.07.15.724605 (2026).","DOI":"10.64898\/2026.07.15.724605"},{"key":"1361_CR14","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41590-022-01274-3","volume":"23","author":"RS Herati","year":"2022","unstructured":"Herati, R. S. et al. PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. Nat. Immunol. 23, 1183\u20131192 (2022).","journal-title":"Nat. Immunol."},{"key":"1361_CR15","doi-asserted-by":"publisher","unstructured":"Ngiow, S. F. et al. PD-1 blockade drug holiday improves exhausted progenitor CD8 T cell (Tpex) reinvigoration by avoiding Tpex adaptive resistance. Preprint at bioRxiv https:\/\/doi.org\/10.64898\/2026.05.14.725199 (2026).","DOI":"10.64898\/2026.05.14.725199"}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01361-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:01:59Z","timestamp":1793106119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01361-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1361"],"URL":"https:\/\/doi.org\/10.1038\/s41577-026-01361-8","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"28 September 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.J.W. is an advisor for Arpelos Bio, Arsenal Biosciences, Coherus, Danger Bio, IpiNovyx, New Limit, Marengo, Pluto Immunotherapeutics, Related Sciences, Santa Ana Bio and Synthekine; is a founder of Arpelos Bio, Arsenal Biosciences and Danger Bio; and holds stock in Coherus.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}